SEATTLE–(BUSINESS WIRE)– LumiThera anuncia el inicio del estudio de registro EUROLIGHT para evaluar los beneficios a largo plazo del tratamiento de fotobiomodulación (PBM, por sus siglas en inglés) utilizando el Valeda® Light Delivery System en paci…
Author: Business Wire
Aviceda Therapeutics gibt Topline-Daten von Teil 1 der klinischen Phase-2/3-SIGLEC-Studie für AVD-104 bekannt, die eine positive Sicherheitsbewertung und eine frühe klinische Wirksamkeit bei Patienten mit geografischer Atrophie belegen
CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Aviceda Therapeutics, ein im klinischen Stadium tätiges Biotech-Unternehmen, dessen Schwerpunkt auf der Entwicklung neuartiger Glyko-Immuntherapeutika liegt, die das körpereigene Immunsystem zur Modulation von…
Riassunto: Aviceda Therapeutics annuncia i dati di punta dalla Prima parte dello studio clinico di fase 2/3 SIGLEC per AVD-104, dimostrando la sicurezza positiva e l'efficacia clinica precoce nei pazienti affetti da atrofia geografica
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, società biotecnologica allo stadio clinico incentrata sullo sviluppo di nuovi farmaci gluco-immunitari utilizzando il sistema immunitario naturale dell’organismo per modulare l’infiammazione graz…
Resumen: Aviceda Therapeutics anuncia los datos generales de la primera parte de la fase 2/3 del ensayo clínico SIGLEC para AVD-104, que revela resultados positivos en cuanto a seguridad y eficacia clínica temprana en pacientes con atrofia geográfica
CAMBRIDGE (Massachusetts, EE. UU.)–(BUSINESS WIRE)–Aviceda Therapeutics, empresa privada de biotecnología especializada en el desarrollo de nuevas terapias glicoinmunes mediante el aprovechamiento del sistema inmunitario natural del cuerpo para regul…
VMG Health Acquires Compliance Risk Analyzer from DoctorsManagement
DALLAS–(BUSINESS WIRE)– #CRA–VMG Health is pleased to announce it has acquired Compliance Risk Analyzer (CRA) from DoctorsManagement.
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-term Benefits of Valeda® Treatments in Dry Age-Related Macular Degeneration Patients.
Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a clinical-stage biotech company focused on developing novel glyco-immune therapeutics by harnessing the body’s natural immune system to modulate inflammation by using highly selective ligands de…
Nordic Group B.V., par l'intermédiaire de sa filiale Amring Pharmaceuticals Inc. annonce la nomination de Jai G. Parekh, MD, MBA, au poste de directeur commercial d’Eye Care U.S.
BERWYN, Pennsylvanie–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filiale de Nordic Group B.V. (Nordic Pharma), annonce la nomination de Jai G. Parekh, MD, MBA au poste de directeur commercial chez Eye Care U.S. Nordic Pharma a récemment dév…
Riassunto: Nordic Group B.V. annuncia tramite la sua affiliata Amring Pharmaceuticals Inc. la nomina del dott. Jai G. Parekh, MBA, come Direttore commerciale di Eye Care negli USA
BERWYN, Pennsylvania (USA)–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), società affiliata di Nordic Group B.V. (Nordic Pharma), ha annunciato la nomina del dott. Jai G. Parekh, MBA, in qualità di Direttore commerciale di Eye Care negli USA. …
Nordic Group B.V. gibt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Ernennung von Jai G. Parekh, MD, MBA zum Chief Commercial Officer, Eye Care U.S. bekannt
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), eine Tochtergesellschaft der Nordic Group B.V. (Nordic Pharma), gibt bekannt, dass Jai G. Parekh, MD, MBA, Chief Commercial Officer von Eye Care U.S. wird Nordic Pharma hat vor kurzem …
Samenvatting: Nordic Group B.V. kondigt via haar dochteronderneming Amring Pharmaceuticals Inc. de benoeming aan van Jai G. Parekh, MD, MBA, als Chief Commercial Officer, Eye Care V.S.
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), een dochteronderneming van Nordic Group B.V. (Nordic Pharma), kondigt aan dat Jai G. Parekh, MD, MBA, Chief Commercial Officer, Eye Care V.S. wordt. Nordic Pharma heeft onlangs zijn fa…
Resumen: Nordic Group B.V., a través de su filial Amring Pharmaceuticals Inc., anuncia el nombramiento del Dr. Jai G. Parekh como director comercial para el cuidado ocular en EE. UU.
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), filial de Nordic Group B.V. (Nordic Pharma), anuncia el nombramiento del Dr. Jai G. Parekh como director comercial para el cuidado ocular en EE. UU. Nordic Pharma ha expandido reciente…
Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
BERWYN, Pa.–(BUSINESS WIRE)–Amring, a subsidiary of Nordic Group B.V. (Nordic Pharma), announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.
Drug Farm Receives Rare Pediatric Disease Designation from the U.S. FDA for DF-003 to Treat ROSAH Syndrome
GUILFORD, Conn.–(BUSINESS WIRE)–Drug Farm, a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s alpha-kinase 1 (ALPK1) inhibitor, …
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug…
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
GENEVA–(BUSINESS WIRE)–Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced…
Bifrost Biosystems Launches with Novel Optical Pooled Screening Technology to Power Efficient Discovery
CAMBRIDGE, Mass.–(BUSINESS WIRE)– #JPM24–Bifrost Biosystems announced today its launch with a vision to power efficient drug discovery through its novel automated Optical Pooled Screening (OPS) platform. The Bifrost OPS platform uniquely integrates …